semaglutide mastery course
Unit 11 of 12

comparative efficacy

head-to-head data, mechanism differences, and clinical selection factors

comparative efficacy

Semaglutide does not exist in isolation. Tirzepatide, the dual GIP/GLP-1 agonist, has shown greater weight loss in head-to-head trials. Liraglutide, the first-generation daily GLP-1 agonist, remains widely prescribed with a longer safety track record. This unit compares mechanism differences, clinical trial results across weight loss and glycemic endpoints, cardiovascular outcome data, and the practical factors that drive selection between agents.

The paid sections break down the SURMOUNT-5 head-to-head (tirzepatide's ~47% greater weight loss), the liraglutide mechanism and tolerability contrast, the full GLP-1RA class on a single efficacy/safety matrix, and a decision framework for when semaglutide still wins on cardiovascular, renal, or oral-route criteria.

Interactive Visualization

compare GLP-1 agonists across efficacy, safety, cost, and convenience dimensions.

GLP-1 agonist comparison matrix
~47%
greater relative weight loss with tirzepatide vs semaglutide 2.4 mg in head-to-head data (-20.2% vs -13.7%)
HR 0.80
MACE reduction in SELECT -- semaglutide's cardiovascular outcome advantage, with data in non-diabetic obesity that tirzepatide lacks
2.7% vs 5.6%
GI discontinuation rates favoring tirzepatide despite greater efficacy -- likely due to biased GLP-1R agonism reducing nausea dynamics
~8%
liraglutide weight loss (3.0 mg daily) -- roughly half of semaglutide's effect, but with faster washout relevant for pregnancy planning
efficacy vs access. Head-to-head weight-loss data favors tirzepatide, but semaglutide retains unique advantages: cardiovascular outcome data in non-diabetic obesity (SELECT), dedicated kidney outcomes (FLOW), MASH indication, and the only oral formulation in the GLP-1RA class (Rybelsus). in practice, the "best" drug is often the one the patient can access, afford, and tolerate long-term.

key terms for this unit

G GIP/GLP-1 dual agonism pharmacology
Tirzepatide's mechanism: simultaneous activation of both GIP and GLP-1 receptors, plus biased GLP-1R signaling that reduces receptor internalization. The additional GIP agonism provides direct effects on adipose tissue (lipid buffering, visceral fat mobilization) that semaglutide's single-receptor approach cannot access.
S SURMOUNT-5 clinical trials
The head-to-head trial comparing tirzepatide to semaglutide 2.4 mg in adults with obesity. Confirmed tirzepatide's ~47% greater relative weight loss. Published in the New England Journal of Medicine in 2025, converting years of cross-trial speculation into direct evidence.
L LEADER trial cardiovascular outcomes
Liraglutide's 2016 cardiovascular outcomes trial showing 13% MACE reduction (HR 0.87) in patients with T2D and high CV risk. Semaglutide's SELECT trial showed a larger 20% reduction and extended the evidence to non-diabetic obesity -- a population liraglutide has not been tested in for CV outcomes.
B biased agonism receptor pharmacology
When a ligand preferentially activates certain signaling pathways over others at the same receptor. Tirzepatide's biased GLP-1R signaling may explain its lower GI side effect rates despite greater efficacy -- it reduces the nausea-associated receptor dynamics while maintaining appetite suppression.
H HFpEF (heart failure with preserved ejection fraction) emerging indication
A form of heart failure with few effective treatments. Both semaglutide (STEP-HFpEF) and tirzepatide have shown benefit, with tirzepatide demonstrating particularly robust functional improvement data. This emerging indication may become a key differentiator between agents.